Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of 5 Fixed Doses of BAY85-3934 Administered Orally in the Correction of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease Not Currently Treated With Erythropoiesis-stimulating Agent in Europe and Asia Pacific
Brief Summary: Anaemia is a condition in which blood has a lower than normal number of red blood cells. It can also occur if red blood cells do not contain enough haemoglobin, an oxygen carrying part of blood. Anaemia is common in patients with chronic kidney disease. Healthy kidneys produce a hormone called erythropoietin, which stimulates the bone marrow to produce the proper number of red blood cells needed to carry oxygen to vital organs. Chronic kidney disease is a general term that means that the kidneys are not functioning to their full potential. The study drug, BAY85-3934, is being evaluated as a drug to increase the body's ability to produce erythropoietin.

The purpose of this study is to find out if the study drug, a tablet taken orally, is safe and effective for the treatment of anaemia associated with chronic kidney disease.

The study will enroll 120 patients at multiple locations in Europe, Asia and Australia. Participation will involve a screening visit and between 12 and 14 study visits scheduled over a period of approximately 5 to 7 months. The estimated total duration of study treatment will be 16 weeks. During these scheduled visits patients will undergo a number of procedures to confirm efficacy and safety of the study drug, including measurement of heart rate and blood pressure, physical examination, Electrocardiogram and blood/urine sample collection for laboratory tests.

The study will be conducted at 5 hospitals in the UK. Bayer HealthCare AG is funding this research.


Options:
A: Arm Label: Darbepoetin Alfa Injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Desidustat oral tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desidustat Oral Tablet | Intervention Type: DRUG; Name: Desidustat Oral Tablet; Assigned to Arm(s): Desidustat oral tablet | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin Alfa Injection
B: Arm Label: ASP1517 Group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: Darbepoetin alfa Group; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): ASP1517 Group | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa Group
C: Arm Label: BAY85-3934 (25mg OD); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: BAY85-3934 (50mg OD); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: BAY85-3934 (75mg OD); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: BAY85-3934 (25mg BID); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: BAY85-3934 (50mg BID); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934, Drug: Placebo | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAY85-3934; Assigned to Arm(s): BAY85-3934 (25mg BID), BAY85-3934 (25mg OD), BAY85-3934 (50mg BID), BAY85-3934 (50mg OD), BAY85-3934 (75mg OD) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BAY85-3934 (25mg BID), BAY85-3934 (25mg OD), BAY85-3934 (50mg BID), BAY85-3934 (50mg OD), BAY85-3934 (75mg OD), Placebo BID
D: Arm Label: AKB-6548; Type: EXPERIMENTAL; Interventions: Drug: AKB-6548 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AKB-6548; Assigned to Arm(s): AKB-6548 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C